Literature DB >> 22218923

Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.

Anna Maria Farca1, B Miniscalco, P Badino, R Odore, P Monticelli, A Trisciuoglio, E Ferroglio.   

Abstract

Despite the availability of different therapeutic options, canine visceral leishmaniosis (CVL) remains a challenging disease to treat. Recently miltefosine has been registered for use in dogs, and different studies have demonstrated its leishmanicidal effect. Moreover, it has been suggested that fluoroquinolones, compared to standard chemotherapeutic agents, could be an effective and pragmatic alternative to treat CVL. The efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum was assessed in vitro by incubating increasing concentrations of the drugs with a standard parasite inoculum. Miltefosine was significantly more efficacious than marbofloxacin (P < 0.05) against the two strains of L. infantum either alone or in combination with allopurinol. Both drugs were significantly (P < 0.05) more efficacious when associated with allopurinol than alone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22218923     DOI: 10.1007/s00436-011-2792-7

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  35 in total

1.  Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo.

Authors:  W Raether; H Seidenath; J Hofmann
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

2.  Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum.

Authors:  T Cavaliero; P Arnold; A Mathis; T Glaus; R Hofmann-Lehmann; P Deplazes
Journal:  J Vet Intern Med       Date:  1999 Jul-Aug       Impact factor: 3.333

3.  Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.

Authors:  Ioannis Vouldoukis; Sandrine Rougier; Bernard Dugas; Paco Pino; Dominique Mazier; Frédérique Woehrlé
Journal:  Vet Parasitol       Date:  2005-10-19       Impact factor: 2.738

Review 4.  Treatment of canine Old World visceral leishmaniasis: a systematic review.

Authors:  Chiara Noli; Silvia T Auxilia
Journal:  Vet Dermatol       Date:  2005-08       Impact factor: 1.589

5.  In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.

Authors:  Karin Seifert; Patricia Escobar; Simon L Croft
Journal:  J Antimicrob Chemother       Date:  2010-01-20       Impact factor: 5.790

6.  Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi.

Authors:  K M Slunt; J M Grace; T L Macdonald; R D Pearson
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells.

Authors:  D Berkovic; U Grunwald; W Menzel; C Unger; W Hiddemann; E A Fleer
Journal:  Eur J Cancer       Date:  1995-11       Impact factor: 9.162

8.  In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Authors:  Marieke Vermeersch; Raquel Inocêncio da Luz; Kim Toté; Jean-Pierre Timmermans; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  Leishmania major: infection of human monocytes induces expression of IL-8 and MCAF.

Authors:  R Badolato; D L Sacks; D Savoia; T Musso
Journal:  Exp Parasitol       Date:  1996-01       Impact factor: 2.011

10.  Bacteremia caused by Corynebacterium amycolatum with a novel mutation in gyrA gene that confers high-level quinolone resistance.

Authors:  Seoyoung Yoon; Heejung Kim; Yangsoon Lee; Sinyoung Kim
Journal:  Korean J Lab Med       Date:  2011-01
View more
  3 in total

1.  Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca2+ Channel.

Authors:  Andrea K Pinto-Martinez; Jessica Rodriguez-Durán; Xenon Serrano-Martin; Vanessa Hernandez-Rodriguez; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Wendel Coura-Vital; Henrique Gama Ker; Nádia das Dores Moreira; Juliana Vitoriano-Souza; Rodolfo Cordeiro Giunchetti; Cláudia Martins Carneiro; Alexandre Barbosa Reis
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

Review 3.  Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.

Authors:  Bruno L Travi; Anabela Cordeiro-da-Silva; Filipe Dantas-Torres; Guadalupe Miró
Journal:  PLoS Negl Trop Dis       Date:  2018-01-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.